Abstract Details

Title An increase in the prevalence of Multiple Sclerosis has moved Kuwait to a high-risk zone

Topic General Neurology

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-009

Objective

To update the prevalence and incidence rates of MS among Kuwaiti nationals

Background The national MS registry (established in 2010) continues to assess the change in epidemiological status. The last reported data was in 2012

Design/Methods This cross-sectional study was conducted by extracting data from the national registry. Patients with a diagnosis of MS according to 2017 revised McDonald criteria were identified. Patients with possible MS or other demyelinating disorders were excluded. Population census with a cutoff on 30^thJune 2018 was obtained from Kuwait Bureau of Statistics to determine the number of people at risk. The crude, age- and sex-specific prevalence and incidence rates among Kuwaiti Patients were calculated.

Results Results:1722 MS patients were identified of which 1454 (84.4%) were Kuwaitis. Women represented 66.8% of the cohort with female to male ratio of 2.01:1. The mean age of the cohort was 36.7 ±10.7years while the mean age at onset and disease duration were 27.2 ±8.8 and 10.1 ±7.3 years respectively. The point prevalence of MS was 104.88 (95% CI: 89.5-121.9) per 100,000 persons, which increased 1.6 times since 2012. Women had a prevalence of 137.1 (95% CI: 129.3-145.3) compared to men 71.2 (95% CI: 65.3-77.6). The prevalence among the age ranges of ≤19, 20–29, 30–39, 40-39, 50-59, and ≥ 60 years were 15.5, 147.8, 271.4, 230.9, 174.4 and 36.9 per 100,000 persons respectively. The incidence of MS was 5.39 (95% CI: 4.3-6.8) per 100,000 persons. The 5-year incidence was 6.4, which has been stable since the last reported rate.

Conclusions
Conclusion:There is an ongoing increase in the prevalence of MS. According to the Kurtzke geographical distribution, Kuwait is considered a high-risk geographical area for MS. Women had a higher prevalence with a peak among patients aged 30–39 years. The incidence rate has been stable throughout the last 5 years.

Authors/Disclosures
Raed Alroughani, MD, FAAN PRESENTER	Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.
	No disclosure on file
	No disclosure on file
Samar F. Ahmed, MD	Dr. Ahmed has nothing to disclose.
	No disclosure on file
Shashishekha J. Lamdhade, MD (Al Amiri Hospital)	No disclosure on file
Jasem Y. Al-Hashel, MD (IBN Sina Hospital, AlSabah Medical Area, Neurology Department)	Dr. Al-Hashel has nothing to disclose.

��ɫ��

��ɫ��